



Accelerating science.
Transforming health.
Expanding human potential.

This is Revvity.

A proven history.

We're committed to revolutionizing the future of health. Working together with our customers, we're making an impact by addressing some of the world's greatest health challenges:

Revvity Omics' state-of-the-art, clinical grade global network that provides cumulatively more than 300 million cutting-edge genOMICS tests for genetic disorder identification to individuals worldwide 300M	More than 550 mentions of the T-SPOT™.TB test in peer reviewed publications as demonstrating excellent performance in clinical and epidemiological settings 550
868M 868 million babies screened cumulatively for life-threatening disorders with Revvity technologies	Introducing over 1,500 new antibodies, kits, and reagents for life science research annually 1.5K
94% Delivering solutions and services used by 94% of the top global pharmaceutical companies	Supplying Revvity's software solutions to more than two million scientists across pharma, biotech, and academia 2M

Embracing the impossible.

At Revvity, "impossible" is inspiration.


We provide health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure.

Revvity is pushing the limits of what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics, and more.

Every day, our 11,000 employees collaborate to pioneer groundbreaking solutions that enable our customers to improve health outcomes around the world. With a robust global network and localized agility, we serve a diverse range of organizations from pharmaceutical and biotech, to clinical labs, academia, and governments.

No challenge is too great for our team. Together with our customers and partners, we are united in impact, embracing the impossible to improve lives everywhere.

- Founded: 2023**
- President and CEO: Prahlad Singh**
- Headquarters: 77 4th Avenue Waltham, MA 02451**
- Part of the S&P 500 Index**
- NYSE Listed**



Our specialized areas of focus include:



Translational multi-omics technologies



Screening



Biomarker identification



Detection and diagnosis



Imaging



Informatics



Prediction



Customized offerings

Revvity brand portfolio includes:

euroimmun
From Revvity

BioLegend
From Revvity

ViaCord
From Revvity

Tulip

Pioneering what's next.

What if the benefits of leading-edge health science were accessible to everyone, everywhere? We're committed to making this vision a reality by addressing the biggest threats to health today, and fearlessly facing tomorrow's unknowns.

Our scope, reach and ability to make an impact has never been greater.

Groundbreaking therapies. Breakthrough treatments. Revolutionary solutions. All in the name of our purpose: **to expand the boundaries of human potential through science.**

Bring on tomorrow. We're ready for it.

revvity